TY - JOUR T1 - Cardioprotective effects of inhaled corticosteroid-containing combination therapy in COPD JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.02420-2018 VL - 53 IS - 2 SP - 1802420 AU - Brian J. Lipworth AU - Chris R.W. Kuo Y1 - 2019/02/01 UR - http://erj.ersjournals.com/content/53/2/1802420.abstract N2 - The pooled post hoc analysis of three randomised controlled trials by Vestbo et al. [1] found that combinations containing inhaled corticosteroid (ICS) significantly reduced non-respiratory-related mortality in chronic obstructive pulmonary disease (COPD) compared to long-acting bronchodilator therapies alone, the difference amounting to −35% (95% CI −57% to −3%). These studies did not adjudicate on cause of death and only followed patients for up to 1 year. In the IMPACT trial, all-cause mortality was 42% lower and cardiovascular attributed deaths were 52% lower when comparing triple therapy to combined long-acting bronchodilators over 1 year [2].We propose that combination therapy containing inhaled corticosteroids may confer cardioprotective effects in patients with COPD http://ow.ly/AwQG30nmGa9 ER -